Editorial: Current and Emerging Treatments for Methamphetamine Use Disorder

2021 ◽  
Vol 19 (12) ◽  
pp. 2058-2059
Author(s):  
Anna Moszczynska

2021 ◽  
Vol 19 ◽  
Author(s):  
Anna Moszczynska

: Almost two decades have passed since the last methamphetamine (METH) abuse epidemic. In recent years, METH abuse in the US has been rapidly increasing and is currently one of the leading causes of death in our country. Available statistical data indicates re-emergence of METH popularity and suggest an impending third epidemic of METH abuse. Alarmingly, there is no FDA- approved medication for METH use disorder (MUD). This disorder is currently treated with behavioral therapies; however, these therapies have limitations and would benefit from the addition of a MUD pharmacotherapy. Unfortunately, clinical trials have not yet found consistently effective pharmacotherapy for MUD. This review outlines the history of METH use, provides information on current prevalence of METH abuse and MUD, describes medications that have been in clinical trials for MUD, and addresses current as well as potential new treatments for MUD.


2021 ◽  
Vol 224 (2) ◽  
pp. S401-S402
Author(s):  
Marcela Smid ◽  
Amanda A. Allshouse ◽  
Kristine Campbell ◽  
Michelle P. Debbink ◽  
Adam G. Gordon ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Akhil Sharma ◽  
Arman Harutyunyan ◽  
Bernard L. Schneider ◽  
Anna Moszczynska

AbstractThere is no FDA-approved medication for methamphetamine (METH) use disorder. New therapeutic approaches are needed, especially for people who use METH heavily and are at high risk for overdose. This study used genetically engineered rats to evaluate PARKIN as a potential target for METH use disorder. PARKIN knockout, PARKIN-overexpressing, and wild-type young adult male Long Evans rats were trained to self-administer high doses of METH using an extended-access METH self-administration paradigm. Reinforcing/rewarding properties of METH were assessed by quantifying drug-taking behavior and time spent in a METH-paired environment. PARKIN knockout rats self-administered more METH and spent more time in the METH-paired environment than wild-type rats. Wild-type rats overexpressing PARKIN self-administered less METH and spent less time in the METH-paired environment. PARKIN knockout rats overexpressing PARKIN self-administered less METH during the first half of drug self-administration days than PARKIN-deficient rats. The results indicate that rats with PARKIN excess or PARKIN deficit are useful models for studying neural substrates underlying “resilience” or vulnerability to METH use disorder and identify PARKIN as a novel potential drug target to treat heavy use of METH.


2020 ◽  
Vol 77 (3) ◽  
pp. 246 ◽  
Author(s):  
Phillip O. Coffin ◽  
Glenn-Milo Santos ◽  
Jaclyn Hern ◽  
Eric Vittinghoff ◽  
John E. Walker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document